Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And this is true:
"Nanotechnology will be changing the world in ways that we can't even imagine now. And like the paths of those earlier "big ideas," nanotech is just beginning to scratch the surface - giving investors another chance to beat the crowd."
Ann
MonkeyNinja:
In this point in time, I agree with you.
Take care,
Ann
Sam:
Think a Venture Capitalist?
Take care,
Ann
(no date):
Earthfirst Technologies, Incorporated Company Information
Electrical contracting gives EarthFirst Technologies the power to pursue its interests in turning waste into energy. Subsidiary Electric Machinery Enterprises (EME) is an electrical contractor and accounts for nearly all of EarthFirst Technologies' sales, but the company is also developing technologies to dispose of and recycle waste products. EarthFirst Technologies' vacuum distillation reactor treats such solid waste products as discarded rubber tires; the company's plasma reactor breaks down waste liquids (used oil, grease, and antifreeze) to produce a synthetic gas; another unit produces alternative fuels. Chairman John Stanton owns nearly 60% of EarthFirst.
Is he the same person? FYI Stock
Ann
You will find this most interesting:
Sorry, for so many posts - PROFILE*
John Stanton
Chairman of the Board, Chief Executive Officer and President , EarthFirst Technologies Inc. 2020
Age Total Annual Compensation This person is connected to 20 board members in 7 different organizations across 5 different industries.
BACKGROUND*
John D. Stanton has been Chief Executive Officer and President of EarthFirst Technologies Inc. since February 13, 2006. Mr. Stanton has been Chairman and Chief Financial Officer of Nanobac Pharmaceuticals Inc. since March 2001 and Chief Executive Officer since July 23, 2004. Mr. Stanton served as Chief Executive Officer of PowerCerv Corporation until September 2005. He served as Chief Executive Officer of Nanobac Pharmaceuticals Inc. from March 2001 to January 2004 and was Principal Accounting Officer.
Ann
Info on our buyout co.:
"Nanobac Pharmaceuticals wants to pick on something much smaller than its own size. The company is researching and developing treatments for diseases caused by nanobacteria, tiny organisms that are 100 times smaller than bacteria, yet cause the body to develop calcium buildup in inconvenient places such as artery walls and kidneys. In addition, nanobacteria can be resistant to antibiotics, radiation, or temperature extremes. At present Nanobac has developed diagnostic tests to identify nanobacteria in the blood. The company was formed when diagnostic imaging firm American Enterprise Corporation bought and merged with NanobacLabs Pharmaceuticals. CEO John Stanton controls nearly 40% of the company.
Ann
Nanobac & the NASA experience:
http://www.spacedaily.com/news/life-04zzzr.html
Ann
Nanobac News release w/no year attached:
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/10-04-2004/0002265175&EDATE=
Ann
Sounds good to me...
""We are pleased to have Guy and his exceptional team working with us on protecting our intellectual property estate," stated John Stanton, Nanobac's Chairman and CEO. "We are at a true turning point at Nanobac with our science, our products and our partnerships, and we need to protect our intellectual property estate."
Ann
FIY from Nanobac board:
Posted by: jolyn86
In reply to: Brothers In Arms who wrote msg# 399 Date:2/3/2008 7:09:46 PM
Post #of 423
Scottie in the NNBP news. The NNBP wants to buy back 20% of the float.. Seems there is a lot of bashing on the DNAG boards. Odds are they could be a lot DNAG shorts caught off guard.
Monday I will try to buy 400,000 shares of DNAG under 0.005
I am holding my NNBP
Ann
Posted on Nanobac board:
Posted by: nanopatent
In reply to: None Date:2/1/2008 12:36:29 PM
Post #of 423
DNAPrint Genomics patent position
Results of Search in US Patent Collection db for:
AN/"DNAPrint Genomics": 2 patents.
PAT. NO.
Title 1
7,110,885
Efficient methods and apparatus for high-throughput processing of gene sequence data
2
7,107,155
Methods for the identification of genetic features for complex genetics classifiers
http://tinyurl.com/22t8nb
Results of Search in PGPUB (Published Applications) (Published Applications) Production Database for:
AN/"DNAPrint Genomics": 1 applications.
Hits 1 through 1 out of 1
PUB. APP. NO.
Title
1
20070020651
Compositions and methods for the inference of pigmentation traits
http://tinyurl.com/22k4ql
RESULT LIST
14 results found in the Worldwide database for:
DNAPrint Genomics as the applicant
http://tinyurl.com/2eaovq
Looks good, promising and most of all - tremendously PROFITABLE.
Agreed?!!!!!
Time to load the boat - remember Mayo, NASA, China, Finland, Canada (anybody I forgot?).
A post to read and share,
Ann
Froggie:
"Looks like a lot of wiggle room has been inserted with that "or".
Good or bad.
Take care all,
Ann
Important Agreement:
http://www.hoovers.com/free/co/secdoc.xhtml?ID=107230&ipage=5692143-16066-19086
Ann
Acquisition of Buyer by Seller:
http://www.hoovers.com/free/co/secdoc.xhtml?ID=107230&ipage=5692143-4200-15947
Ann
8-K filed 2/04/08:
http://www.hoovers.com/free/co/secdoc.xhtml?ID=107230&ipage=5692143
Ann
A positive:
"Nanobac Announces European Heart Journal Publication of Association Between Calcifying Nanoparticles and Aortic Stenosis
BUSINESS WIRE
Posted: 2008-01-22 11:01:18
TAMPA, Fla.--(BUSINESS WIRE)----Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces the multicenter publication of independent research which reports an association between calcifying nanoparticles (CNPs) and aortic stenosis. Aortic stenosis represents the most frequent cause of heart valve replacement (Bratos-Perez et al, European Heart Journal Advance Access, doi:10.1093/eurheartj/ehm592).
The authors contend: "For the first time, this study shows that CNP could be causally related to aortic stenosis in humans. We suggest that CNPs colonize the aortic valve, provoking an inflammatory response, resulting in valve calcification via two distinct mechanisms: directly given their capacity to precipitate calcium in the shape of apatite crystals, at physiological calcium and phosphate concentrations, and indirectly by activating the inflammatory pathways."
Ann
Nanobac Pharmaceuticals changes name:
http://www.biospace.com/company_profile.aspx?CompanyId=674720
Ann
Could John Stanton be our venture capitalist?
"John D. Stanton Co-chairman, Chief Executive Officer and Chief Financial Officer From March, 2001 through the present, Mr. Stanton has served as our Chairman of the Board and Chief Financial Officer. From March 2001 through January 2004, Mr. Stanton served as Chief Executive Officer and since July 2004 took over that role again. From 1987 through the present, Mr. Stanton served as the President and Chief Executive Officer of Florida Engineered Construction Products, Corporation. Mr. Stanton has served as Chairman of the Board of Directors of publicly-traded EarthFirst Technologies, Inc. from May 15, 2000 through the present. Mr. Stanton also serves on the Med-Tech Board of Directors. Since the early 1990's, Mr. Stanton has been, and continues to be, involved in turn-around management for financially distressed companies, providing management guidance and financing. In 1981, Mr. Stanton assumed the role of Chief Financial Officer for Florida Engineered Construction Products, Corporation, a privately held manufacturer of residential and commercial construction products, located in Tampa, Florida. Mr. Stanton worked as an auditor with the international professional services firm that is now known as Ernst & Young, LLP from 1973 through 1981. A Vietnam veteran of the United States Army, he graduated from the University of South Florida with a Bachelors Degree in Marketing and Accounting in 1972, and with an MBA in 1973. Mr. Stanton earned the designation of Certified Public Accountant in 1974 and was a Sells Award winner in the CPA examination. Mr. Stanton is a lifetime resident of Tampa, Florida."
Abb
Nanobac/DNAP:
"With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development. Nanobac adds advanced drug and diagnostics development programs, key patents and patent applications, and a proprietary product modeling platform to its existing initiatives, and expands its focus into multiple disease sites for both Diagnostics and Therapeutics.
The combined company would have annualized revenue of approximately $5,000,000, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University.
Ann
The only post of the day...
Amen - (lol)
Ann
Nano Technology:
Nanobac on You Tube:
Nanobac's development strategy:
"Our development strategy is to enter into partnerships with pharmaceutical and biotechnology partners who have the capability and infrastructure to successfully market products around the world.
Nanobac is interested in discussing opportunities for strategic alliances with pharmaceutical and biotechnology companies."
Ann
Nanobac acquisition:
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company”) is pleased to announce a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc. (OTCBB:DNAG - News) (“DNAPrint” or DNAP). With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development
Ann
Nanobac Pharmaceuticals has patented a range of drug combinations, consisting of well known and safe ingredients, shown convincingly to eradicate nanobacteria in vitro, as published by the U.S. Patent and Trade Office.
Ann
Alter:
So are: ASTRA, ZENECA, PHILLIPS, HUMANA & BG MEDICINE
Ann
What are you referring to, Altar...?
thanks, just the same.
Happy Sunday,
Ann
Impressive credentials:
E. Olavi Kajander, MD, Ph.D.
Chief Research and Science Officer
Dr. E. Olavi Kajander is Chief Research and Science Officer at Nanobac Pharmaceuticals in Tampa. He founded Nanobac OY, a Finnish research and development company located in Kuopio, Finland which is is now a subsidiary of Nanobac Pharmaceuticals. Dr. Kajander also founded Abcell Corporation, a medical diagnostics company.
Dr. Kajander is a professor at the University of Kuopio. His position at the University of Kuopio has elevated over the time of his tenure from Ph.D. candidate, to doctorate, assistant professor, associate professor and now as docent. He has taught many courses at the university for more than 12 years and was the Research Director in the Department of Biochemistry.
Dr. Kajander was a Scripps Clinic & Resident Foundation post-doctoral research fellow in La Jolla, California. He has authored or co-authored more than 70 scientific research papers and review articles, two letters and more than 50 scientific abstract publications as well as several invited editorials in scientific texts and journals. He also co-authored a Microbiology textbook chapter on Nanobacteria. He has been involved in the production of a number of videos and documentaries about his discovery of Nanobacteria. He pioneered families of U.S. patents effective in many countries and now assigned to Nanobac Pharmaceuticals.
Ann
Nanobac Remarkable Discoveries:
http://www.nanobaclabs.com/content/discoveries.htm
Ann
Merck Laboratories is one of Nanobac's five HRP initiave partners -
Ann
Here's why:
Here is why Nanobac Pharmaceuticals is important for investors:
Calcification and inflammation afflict most of our aging population. Nanobac Pharmaceuticals is the only company with patented methods to show that a tiny nanoparticle known commonly as nanobacteria produces a calcified coating which is the same material as found in disease-related calcified deposits.
These nanobacteria have been discovered in the calcified deposits of heart disease, arthritis and kidney disease, as published in leading journals. See the Publications section of our website for information. This is the only credible scientific evidence of a particle that provokes calcification.
Ann
Nanobac seems to have an office in Finland. (listed on their website).
Ann
Nanobac agreements for Middle East:
http://www.tradingmarkets.com/.site/news/Stock%20News/758921/
Ann
Posted on Nanobac board:
Posted by: nanopatent
In reply to: None Date:2/7/2008 9:30:58 AM
Post #of 413
Nanobac Pharmaceuticals Inc. Engages Legal Team to Enforce Patent Rights
Last update: 9:15 a.m. EST Feb. 7, 2008
TAMPA, Fla., Feb 07, 2008 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. ("Nanobac" or "the Company") is pleased to announce that it has engaged Guy Ricciardulli for services related to claims for damages, injury or loss out of patent infringement.
"We are pleased to have Guy and his exceptional team working with us on protecting our intellectual property estate," stated John Stanton, Nanobac's Chairman and CEO. "We are at a true turning point at Nanobac with our science, our products and our partnerships, and we need to protect our intellectual property estate."
Ann
Wow, Altar - would be nice is that post was true.
Take care,
Ann
ptgame:
"With this acquisition my hope is renewed"
Agreed. It is discouraging, however, to see the pps go so low.
The finalized date of agreement is May,08. "Wait & See" as for so many years.
I'm going to try to keep the optimism also. In all honesty, I feel much better when I can read posts such as yours - like a "shot in the arm." - lol
Take care,
Ann
Monkeyninja:
Nice to read an optimistic post today.
Take care,
Ann
ptgame:
You're welcome and since we're being acquired by Nanobac, nice to know and perform all DD and gather information of what the company has to offer.
Ann